Author
Listed:
- Liwei Zhu
(Guangzhou Medical University)
- Guangjie Song
(Shenzhen University)
- Wentian Zhang
(Guangzhou Medical University)
- Yifan Wu
(Guangzhou Medical University)
- Yuling Chen
(Guangzhou Medical University)
- Jiayi Song
(Guangzhou Medical University)
- Deliang Wang
(Huzhou University)
- Guoxin Li
(Tsinghua University)
- Ben Zhong Tang
(The Chinese University of Hong Kong)
- Ying Li
(Guangzhou Medical University)
Abstract
Multimodal phototheranostics utilizing single molecules offer a “one-and-done” approach, presenting a convenient and effective strategy for cancer therapy. However, therapies based on conventional photosensitizers often suffer from limitations such as a single photosensitizing mechanism, restricted tumor penetration and retention, and the requirement for multiple irradiations, which significantly constrain their application. In this report, we present an aggregation-induced emission luminogen (AIEgen) bacteria hybrid bionic robot to address above issues. This bionic robot is composed of multifunctional AIEgen (INX-2) and Escherichia coli Nissle 1917 (EcN), i.e., EcN@INX-2. The EcN@INX-2 bionic robot exhibits near-infrared II (NIR-II) fluorescence emission and demonstrates efficient photodynamic and photothermal effects, as well as tumor-targeting capabilities. These features are facilitated by the complementary roles of INX-2 and EcN. The robot successfully enables in vivo multimodal imaging and therapy of colon cancer models in female mice through various mechanisms, including the activation of anti-tumor immunity, as well as photodynamic and photothermal therapy. Our study paves an avenue for designing multifunctional diagnostic agents for targeted colon cancer therapy through image-guided combinational immunotherapy.
Suggested Citation
Liwei Zhu & Guangjie Song & Wentian Zhang & Yifan Wu & Yuling Chen & Jiayi Song & Deliang Wang & Guoxin Li & Ben Zhong Tang & Ying Li, 2025.
"Aggregation induced emission luminogen bacteria hybrid bionic robot for multimodal phototheranostics and immunotherapy,"
Nature Communications, Nature, vol. 16(1), pages 1-18, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57533-y
DOI: 10.1038/s41467-025-57533-y
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57533-y. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.